At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TERN Terns Pharmaceuticals, Inc.
Post-Mkt 01-13 19:25:18 EST
34.45
+0.34
+1.00%
盘后34.50
+0.05+0.15%
18:59 EST
High35.60Low33.72Vol2.21M
Open34.08D1 Closing34.11Amplitude5.51%
Mkt Cap3.76BTradable Cap2.77BTotal Shares109.00M
T/O77.03MT/O Rate2.76%Tradable Shares80.32M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

De-Risked CML Lead Asset, Robust Trial Strategy, and $1B Cash Runway Underscore Buy Rating on Terns Pharmaceuticals
TIPRANKS  ·  01-13 21:36
De-Risked CML Lead Asset, Robust Trial Strategy, and $1B Cash Runway Underscore Buy Rating on Terns Pharmaceuticals
TERN-701’s Superior Efficacy and Safety in CML Underpin Buy Rating and Top 2026 Pick on Terns Pharmaceuticals
TIPRANKS  ·  01-13 17:55
TERN-701’s Superior Efficacy and Safety in CML Underpin Buy Rating and Top 2026 Pick on Terns Pharmaceuticals
Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation
Reuters  ·  01-12 21:13
Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation
Will Fast Track TERN-701 Status and $747.5 Million Raise Change Terns Pharmaceuticals' (TERN) Narrative
Simply Wall St.  ·  01-08
Will Fast Track TERN-701 Status and $747.5 Million Raise Change Terns Pharmaceuticals' (TERN) Narrative
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire  ·  01-08
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Terns Pharmaceuticals Chief Medical Officer Emil Kuriakose Reports Disposal of Common Shares
Reuters  ·  01-07
Terns Pharmaceuticals Chief Medical Officer Emil Kuriakose Reports Disposal of Common Shares
Terns Pharmaceuticals Grants Equity Awards to New Employees Under Inducement Plan
Reuters  ·  01-03
Terns Pharmaceuticals Grants Equity Awards to New Employees Under Inducement Plan
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire  ·  01-03
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals (TERN): Valuation Check After Strong CARDINAL Trial Data for CML Candidate TERN-701
Simply Wall St.  ·  2025-12-16
Terns Pharmaceuticals (TERN): Valuation Check After Strong CARDINAL Trial Data for CML Candidate TERN-701
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire  ·  2025-12-12
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Terns Pharmaceuticals Is Maintained at Market Outperform by Citizens
Dow Jones  ·  2025-12-11
Terns Pharmaceuticals Is Maintained at Market Outperform by Citizens
Terns Pharmaceuticals Stock Rises on Public Offerings to Fund TERN-701
Dow Jones  ·  2025-12-11
Terns Pharmaceuticals Stock Rises on Public Offerings to Fund TERN-701
Terns Pharmaceuticals Inc : Jefferies Raises Target Price to $70 From $35
THOMSON REUTERS  ·  2025-12-10
Terns Pharmaceuticals Inc : Jefferies Raises Target Price to $70 From $35
Terns Pharmaceuticals Inc - Prices Upsized Offering of 16,250,000 Shares at $40.00 Each
THOMSON REUTERS  ·  2025-12-10
Terns Pharmaceuticals Inc - Prices Upsized Offering of 16,250,000 Shares at $40.00 Each
Mizuho Raises Price Target on Terns Pharmaceuticals to $54 From $33, Keeps Outperform Rating
MT Newswires Live  ·  2025-12-09
Mizuho Raises Price Target on Terns Pharmaceuticals to $54 From $33, Keeps Outperform Rating
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster
Benzinga_recent_news  ·  2025-12-09
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster
Terns Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  2025-12-09
Terns Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
BRIEF-Terns Announces Proposed Public Offering
Reuters  ·  2025-12-09
BRIEF-Terns Announces Proposed Public Offering
Terns Pharmaceuticals Inc - to Use Proceeds for Research and Tern-701 Development
THOMSON REUTERS  ·  2025-12-09
Terns Pharmaceuticals Inc - to Use Proceeds for Research and Tern-701 Development
Terns Pharmaceuticals Inc - Grants Option for Additional $60 Mln Shares
THOMSON REUTERS  ·  2025-12-09
Terns Pharmaceuticals Inc - Grants Option for Additional $60 Mln Shares
No data available

Introduction

Company Name.
Terns Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Issue price:
--